top of page

Hong Kong Intelligence Report #98 應陽盡陽是屠殺弱勢群體的恐怖主義

Updated: Jan 15

Open-source intelligence (OSINT)

FILE PHOTO: Experimental COVID vaccination © Envato

🔻 IMPORTANT 【重要】


人民至上(動態清零)轉為資本至上,病毒至上(與病毒共存/放棄抗疫)


國家衛健委指,12月8日至前日,全國新增近6萬名住院新冠患者死亡,其中5503人是新冠病毒引發呼吸衰竭致死,其餘都是基礎病合併染疫而死亡。當局指,截至前日,住院新冠患者有127萬人,佔整體住院病人21.7%,其中重症患者仍處於高位,正從上周四的頂峰緩慢回落。目前全國重症床位使用率仍高達75.3%,有多達10.5萬名重症患者,當中以長者為主,有近9成人年滿60歲。


香港總商會總裁梁兆基指,香港與內地已幾乎全面恢復通關,時機亦比商界預期來得早及全面,會員反映對經濟前景更為樂觀,不過陰性檢測等要求仍有一定阻礙,期望兩地很快撤銷相關限制及人流限額。



▪️ 從2022年由香港此一滲透內地的前進基地率先發動的改變中國防疫政策的內外資本攻堅戰上,共有3道中方防線;第一是動態清零政策(2022年11月10/11日20條優化措施起逐漸瓦解,12月7日發稿並12月8日起實施的另10條優化政策徹底拆除了動態清零政策,最後12月26日中國國家衛健委的2023年1月8日起實施免檢疫通關以及撤除隔離措施等決策完成了轉為與病毒共存的不歸路);第二道則是內地禁止西方疫苗;第三道是維護中醫/中藥產業和內地市場。到目前為止,在真政治上,重中之重的正是內地市場嚴禁西方疫苗,是因為這整個反清零運動/作戰的客觀經濟目標正是為西方疫苗公司全面打開內地市場。從2023年1月7日到1月14日為止的發展趨勢中,第二道防線尚未被打破。中港澳大力放開防疫措施中的2023年1月13日被問到中方是否考慮批准中國內地公民接種輝瑞/復必泰mRNA疫苗時外交部就表態了。中方仍然婉拒。內地共有13款內地製造的各種疫苗(覆蓋滅活疫苗、重組蛋白疫苗、病毒載體疫苗等,由中國生物、科興中維、康希諾、智飛生物、康泰生物、萬泰生物、神州細胞、三葉草生物、威斯克生物等製造),不止是科興疫苗,也包括自身正在研發的mRNA疫苗(國藥中生復諾健、石藥集團、斯微生物、艾博生物、麗凡達生物、藍鵲生物、康希諾等)。重點是內地不反對mRNA疫苗本身。不過,隨著疫情惡化和免檢疫通關後香港充當輝瑞/復必泰的次內地市場,伴隨而來的就是內地來港接種者會群起擴大要求中共開放西方疫苗,因此正像動態清零政策,能否堅持多久,這只是個時間的問題。


There are three Chinese lines of defense in the internal and external capital offensive to change China's epidemic prevention policy, spearheaded by Hong Kong as a forward base for infiltration into the Mainland in 2022; the first is the dynamic zero policy (which was gradually dismantled by 20 optimization measures on November 10-11, 2022, and completely dismantled by another 10 optimization policies published on December 7 and implemented from December 8, and finally by the decision of the Chinese National Health Commission on December 26 to implement quarantine-free border clearance and withdraw isolation measures from January 8, 2023). The second is the ban on Western vaccines in the Mainland; the third is the protection of the Chinese medicine industry and the Mainland market. So far, in terms of real politics, the top priority is the strict ban on Western vaccines in the Mainland market because the objective economic goal of this whole anti-zero-COVID campaign/war is to open up the Mainland market to Western vaccine companies. The second line of defense has not yet been broken in the trend of developments from January 7 to January 14, 2023. The Ministry of Foreign Affairs stated its position on January 13, 2023 when asked if the Chinese side would consider approving the Pfizer/ BioNTech mRNA vaccine for mainland Chinese citizens in the midst of the vigorous liberalization of epidemic-prevention measures by China, Hong Kong and Macau. The Chinese side still politely refused. There are 13 mainland-made vaccines of various types (covering inactivated vaccines, recombinant protein vaccines, viral vector vaccines, etc., made by Sino Biopharmaceutical Limited, Sinovac Biotech, CanSino Biologics, Chongqing Zhifei, Shenzhen Kangtai Biological Products, Beijing Wantai Biolog Pha Ent Co Ltd, Shenzhou Cell, Clover Biopharmaceuticals, Westvac Biopharma, etc.), not only CoronaVac vaccine, but also mRNA vaccines under development by itself (Sinopharm Zhongsheng FuNuoJian, Shijiazhuang Pharma Group, Stemirna Therapeutics, Abogen, Aimbio, Blue Magpie Bio, CanSino Biologics, etc.). The main point is that the Mainland does not oppose mRNA vaccines per se. However, as the epidemic worsens and Hong Kong acts as a sub-Mainland market for Pfizer/ BioNTech after quarantine-free border clearance, it is only a matter of time before Mainland vaccine recipients in Hong Kong rise up and demand the opening of Western vaccines from the Chinese Communist Party, so it is just like what happed to the dynamic zero policy.



《北京日報》記者:近日,有西方媒體將中國產的疫苗與輝瑞等外國疫苗效果進行比較,稱中國疫苗效果不佳。發言人對此有何評論?


汪文斌:關於疫苗問題,國務院聯防聯控機制新聞發佈會近來已多次作出回應。我們想指出的是,中國是全球唯一一個同時擁有多種技術路線新冠疫苗產品的國家,為民眾的基礎免疫和加強免疫提供了多種選擇。目前,中國有13款新冠疫苗批准使用,涵蓋4條技術路線,疫苗和醫療物資總體供應充足,能夠滿足「應接盡接」的需要。

世界衛生組織有關負責人最近表示,中國的疫苗接種率非常高,無論是滅活疫苗、病毒載體疫苗還是mRNA疫苗,對預防重症和死亡的保護力相當。相關研究也顯示,對於60歲及以上人群,接種3劑滅活疫苗對重症和死亡的保護效果與接種3針輝瑞mRNA疫苗後的保護效果基本一致。中國全病毒滅活疫苗能夠激發較好的細胞免疫和免疫記憶,在預防發病、重症和死亡中發揮著關鍵作用。中國始終把疫苗的安全性放在首位,中國疫苗的安全性良好,總體不良反應報告率低。當前,中國疫苗全程接種率已達92.9%,60歲以上老年人接種覆蓋率超過90%,我們已向120多個國家和國際組織供應超過22億劑新冠疫苗。實踐證明,中國疫苗是安全、有效的。我們願繼續同國際社會加強溝通合作,更好應對疫情挑戰,更好保護人民生命健康。


Beijing Daily: Some Western media have doubted the efficacy of China-made vaccines after comparing them with products made by other countries such as the Pfizer vaccine. What’s China’s comment?


Wang Wenbin: The State Council joint prevention and control mechanism against COVID-19 has responded to similar questions. We would like to underscore that China is the only country with COVID vaccines developed via multiple technical routes. This provides the public with several choices for getting primary and enhanced immunity. To date, 13 vaccines covering four technical routes have been approved for use in China. Vaccines and medical material are in overall adequate supply, allowing all people eligible for vaccination the access to COVID vaccines.

A WHO official recently said that there are very high coverage levels of vaccination in China and that inactivated vaccines, viral vector vaccines, and mRNA vaccines have all demonstrated high performance of protection against the severe end of the disease spectrum and death. Research also shows that three doses of inactivated vaccine and three doses of the Pfizer mRNA vaccine offer basically equivalent protection against severe or fatal outcomes among adults aged 60 years or older. China-made inactivated vaccines can induce strong cellular immune response and immunological memory. They play an important role in preventing illness, severe cases and death. China always puts first the safety of vaccines. China-made vaccines have a good safety record with overall low adverse event rate.

At present, 92.9% of the Chinese population has been fully vaccinated, with more than 90% of people aged above 60 covered by vac